{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:29:07Z","timestamp":1771540147758,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","funder":[{"name":"Cooperative Research and Development Agreement"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Viamet Pharmaceuticals, Inc"},{"name":"Intramural Research Program"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1093\/jac\/dky170","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T15:39:44Z","timestamp":1524065984000},"page":"2089-2094","source":"Crossref","is-referenced-by-count":31,"title":["VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice"],"prefix":"10.1093","volume":"73","author":[{"given":"Timothy J","family":"Break","sequence":"first","affiliation":[{"name":"Fungal Pathogenesis Section, Laboratory of Clinical Immunology & Microbiology, NIAID, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jigar V","family":"Desai","sequence":"additional","affiliation":[{"name":"Fungal Pathogenesis Section, Laboratory of Clinical Immunology & Microbiology, NIAID, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelley R","family":"Healey","sequence":"additional","affiliation":[{"name":"Public Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Science, Newark, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8908-7306","authenticated-orcid":false,"given":"Mukil","family":"Natarajan","sequence":"additional","affiliation":[{"name":"Fungal Pathogenesis Section, Laboratory of Clinical Immunology & Microbiology, NIAID, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise M N","family":"Ferre","sequence":"additional","affiliation":[{"name":"Fungal Pathogenesis Section, Laboratory of Clinical Immunology & Microbiology, NIAID, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Henderson","sequence":"additional","affiliation":[{"name":"NIH Clinical Center\/Department of Laboratory Medicine, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Zelazny","sequence":"additional","affiliation":[{"name":"NIH Clinical Center\/Department of Laboratory Medicine, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Siebenlist","sequence":"additional","affiliation":[{"name":"Immune Activation Section, Laboratory of Molecular Immunology, NIAID, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M","family":"Yates","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oren J","family":"Cohen","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J","family":"Schotzinger","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S","family":"Perlin","sequence":"additional","affiliation":[{"name":"Public Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Science, Newark, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward P","family":"Garvey","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michail S","family":"Lionakis","sequence":"additional","affiliation":[{"name":"Fungal Pathogenesis Section, Laboratory of Clinical Immunology & Microbiology, NIAID, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,5,16]]},"reference":[{"key":"key\n\t\t\t\t20180724001904_dky170-B1","first-page":"e88782","article-title":"Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy","volume":"11","author":"Ferre","year":"2016","journal-title":"JCI Insight"},{"key":"key\n\t\t\t\t20180724001904_dky170-B2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0163-4453(91)91767-R","article-title":"Fluconazole resistant Candida in AIDS","volume":"22","author":"Fox","year":"1991","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20180724001904_dky170-B3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/jac\/dkm299","article-title":"Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients","volume":"60","author":"Rautemaa","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724001904_dky170-B4","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/myc.12204","article-title":"Vulvovaginal candidiasis: species distribution, fluconazole resistance and drug efflux pump gene overexpression","volume":"57","author":"Zhang","year":"2014","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t20180724001904_dky170-B5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1345\/aph.1C052","article-title":"Treatment of azole-resistant oropharyngeal candidiasis with topical amphotericin B","volume":"36","author":"Grim","year":"2002","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20180724001904_dky170-B6","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/j.bmcl.2014.05.068","article-title":"Design and optimization of highly-selective fungal CYP51 inhibitors","volume":"24","author":"Hoekstra","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"key\n\t\t\t\t20180724001904_dky170-B7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/jac\/dkx352","article-title":"VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans","volume":"73","author":"Break","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724001904_dky170-B8","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.bmcl.2017.06.037","article-title":"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors","volume":"27","author":"Yates","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"key\n\t\t\t\t20180724001904_dky170-B9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/jac\/dkx410","article-title":"Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus","volume":"73","author":"Wiederhold","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724001904_dky170-B10","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts\u2014Third Edition: Approved Standard M27-A3","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"key\n\t\t\t\t20180724001904_dky170-B11","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Fourth Informational Supplement M27-S4","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"key\n\t\t\t\t20180724001904_dky170-B12","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1002\/art.27653","article-title":"The adaptor protein CIKS\/ACT1 is necessary for collagen-induced arthritis, and it contributes to the production of collagen-specific antibody","volume":"62","author":"Pisitkun","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180724001904_dky170-B13","doi-asserted-by":"crossref","first-page":"eaam8834","DOI":"10.1126\/sciimmunol.aam8834","article-title":"Oral epithelial cells orchestrate innate type 17 responses to Candida albicans through the virulence factor candidalysin","volume":"2","author":"Verma","year":"2017","journal-title":"Sci Immunol"},{"key":"key\n\t\t\t\t20180724001904_dky170-B14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1080\/21505594.2016.1186324","article-title":"Batf3-dependent CD103+ dendritic cell accumulation is dispensable for mucosal and systemic antifungal host defense","volume":"7","author":"Break","year":"2016","journal-title":"Virulence"},{"key":"key\n\t\t\t\t20180724001904_dky170-B15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/IAI.02604-14","article-title":"CX3CR1 is dispensable for control of mucosal Candida albicans infections in mice and humans","volume":"83","author":"Break","year":"2015","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20180724001904_dky170-B16","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1128\/AAC.00593-15","article-title":"Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models","volume":"59","author":"Shubitz","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180724001904_dky170-B17","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1128\/AAC.41.6.1392","article-title":"Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans","volume":"41","author":"Klepser","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180724001904_dky170-B18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/ACI.0b013e328358cc0b","article-title":"Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis","volume":"12","author":"Puel","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"key\n\t\t\t\t20180724001904_dky170-B19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-immunol-042617-053318","article-title":"Host control of fungal infections: lessons from basic studies and human cohorts","volume":"36","author":"Lionakis","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"key\n\t\t\t\t20180724001904_dky170-B20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1439-0507.2009.01766.x","article-title":"Investigation of mutations in Erg11 gene of fluconazole resistant Candida albicans isolates from Turkish hospitals","volume":"54","author":"Manastir","year":"2011","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t20180724001904_dky170-B21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/AAC.03470-14","article-title":"Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans","volume":"59","author":"Flowers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180724001904_dky170-B22","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1365-2958.2008.06309.x","article-title":"Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains","volume":"69","author":"Dunkel","year":"2008","journal-title":"Mol Microbiol"},{"key":"key\n\t\t\t\t20180724001904_dky170-B23","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1128\/AAC.00185-15","article-title":"Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis","volume":"59","author":"Garvey","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/8\/2089\/25204767\/dky170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:42:20Z","timestamp":1571186540000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/8\/2089\/4996888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,16]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,5,16]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky170","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,5,16]]}}}